Before, the publicly listed company at the group level had already secured approximately US$ 60 million in convertible bond financing, which will be automatically converted into shares at the price of 2.0 HKD/share on the delivery date.

Dr. Cheney Mao, Chairman and CEO of Viva Biotech, stated that we are pleased to announce the completion of the equity investment and convertible bond arrangement with our strategic investors. This step is pivotal for our future strategic plans, fostering Viva's rejuvenation and sustainable growth, and leading to greater value and returns. At Viva Biotech, innovation remains our cornerstone, as we continuously improve our state-of-the-art technology platforms, fully leveraging the capabilities of our globally recognized drug research and development service platform, among other ventures. Looking ahead, Viva Biotech is committed to maintaining its unique approach to providing comprehensive, one-stop services in drug research, development, and production. Leveraging our extensive experience and unique position in pioneering First-in-class drug discovery, coupled with our comprehensive service offerings, we are dedicated to delivering specialized, customized, full-range services to the global biotech and pharmaceutical industries. This commitment is underpinned by the profound expertise of our highly skilled team of scientists.